Glycated hemoglobin

Glycated hemoglobin is a specific form of hemoglobin that has chemically bonded with a sugar molecule. Hemoglobin is the protein inside red blood cells that carries oxygen throughout the body. When various monosaccharides, such as glucose, galactose, or fructose, are present in the bloodstream, they spontaneously bond with this protein. This bonding process is called glycation, and it occurs without the help of enzymes. While several sugars can trigger this, glucose is the most significant because it serves as the primary metabolic fuel for humans. Measuring these sugar-hemoglobin linkages is vital because high levels often indicate diabetes or other hormone-related diseases.

The chemical mechanism of glycation follows a precise sequence of steps. First, a nonenzymatic condensation reaction occurs between a glucose molecule and the N-end of the hemoglobin's beta chain. This initial reaction produces a temporary structure known as a Schiff base. Following this, the molecule undergoes a second conversion called an Amadori rearrangement. This rearrangement transforms the Schiff base into 1-deoxyfructose. Once this process is complete, the sugar remains permanently attached to the hemoglobin molecule. Because the sugar stays stuck, the amount of glycated hemoglobin reflects the average glucose exposure over the entire life of that red blood cell.

Scientists use the term HbA1c to refer to a specific component of glycated hemoglobin, known as beta-N-1-deoxy fructosyl hemoglobin. The naming of HbA1c comes from how different types of hemoglobin A are separated using cation exchange chromatography. In this process, the first fraction to separate is called HbA0, which is pure hemoglobin A. The subsequent fractions are labeled HbA1a, HbA1b, and HbA1c based on their order of elution. While researchers have since found even more subfractions using improved separation techniques, HbA1c remains the standard for clinical testing.

The history of understanding HbA1c involves several decades of scientific discovery. In 1958, Huisman and Meyering first separated this form of hemoglobin using a chromatographic column. Later, in 1968, Bookchin and Gallop characterized it as a glycoprotein. A major breakthrough occurred in 1969 when Samuel Rahbar and his coworkers described how its levels increase in patients with diabetes. The specific chemical reactions were not fully understood until Bunn and his team characterized them in 1975. Finally, in 1976, Anthony Cerami and Ronald Koenig proposed using HbA1c to monitor glucose metabolism in diabetic patients.

Clinicians rely on the HbA1c test to determine a patient's three-month average blood sugar level. This timeframe is used because the average lifespan of a red blood cell is approximately three to four months. Specifically, the average lifespan is 117 days for men and 106 days for women. Because of this, glucose levels from the most recent days contribute more heavily to the final A1c result than older levels. Laboratories can measure these levels using various methods, including high-performance liquid chromatography, immunoassay, or capillary electrophoresis. Some point-of-care devices used in doctor's offices utilize immunoassay or boronate affinity chromatography.

High levels of glycated hemoglobin can lead to significant biological damage. This process increases highly reactive free radicals inside the blood cells, which alters their cell membranes. This can cause blood cells to aggregate, increasing blood viscosity and impairing blood flow. Furthermore, glycation can trigger inflammation and the formation of atherosclerotic plaques in the arteries. Highly glycated hemoglobin can also interfere with nitric oxide, a potent vasodilator that helps blood vessels relax. This degradation can lead to serious long-term complications, including cardiovascular disease, nephropathy, neuropathy, and retinopathy.

Managing HbA1c levels is a delicate balance for medical professionals. For most diabetic patients, the American Diabetes Association recommends maintaining levels below 7.0% DCCT. However, targets may change based on the individual's specific health needs. For example, more stringent targets below 6.0% might be preferred for pregnant patients. Conversely, intensive therapy to reach very low levels can sometimes increase the risk of dangerous hypoglycemic episodes. For those with conditions like sickle-cell disease or glucose-6-phosphate dehydrogenase deficiency, red blood cells may die prematurely. In these specific cases, doctors might use different tests, such as fructosamine, to assess glucose control over a shorter 2-to-3-week period.